Tsuchiura Kyodo General Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Canani, Luis Henrique S
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Kakuta, Tsunekazu
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
EMPA-AHF, NCT05392764: Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Recruiting
3
524
Japan
Empagliflozin 10 MG, Placebo
Juntendo University, Boehringer Ingelheim
Acute Heart Failure
03/25
12/27
NCT04840914: A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Completed
1
44
Japan, US
LY3461767, Placebo
Eli Lilly and Company
Chronic Heart Failure With Reduced Ejection Fraction
05/24
05/24
JDEPTH-LM, NCT06436092: Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease ( Registry)

Recruiting
N/A
280
Japan
TCROSS Co., Ltd., Kaneka Corporation
Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
05/27
12/29
Osanai, Takayuki
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
Nakagawa, Tsuyoshi
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27

Download Options